9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Advanced Malignant Mesothelioma

Estimated Enrollment: 34

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: Has Results

Outcome Measures: Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST),  Overall Survival,  Progression-free Survival Assessed by RECIST, Determine the Clinical Toxicities of This Drug in This Participant Population.

Interventions: laboratory biomarker analysis, pazopanib hydrochloride

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: April 2009

Completion Date: May 2013

Last  Posted Date: February 24, 2015

Location: North Central Cancer Treatment Group, Rochester, Minnesota, United States

Website Link: https://ClinicalTrials.gov/show/NCT00459862

Was this article helpful?
Dislike 0